Table 1 Characteristics of studies included in the meta-analysis
From: Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis
Study | Region | Tumor type | Detection method and main results | Sample size (high/low) | Follow-up (month) | Endpoints | Cut-off value | Mean age (year) | NOS score | Method |
|---|---|---|---|---|---|---|---|---|---|---|
Filipits et al. [39] | Austria | Diffuse large B-cell lymphoma | IHC (cyclin D3, 30/100) | 31/50 | 30 | OS | High: more than 50% cyclin D3-positive lymphoma cells | NA | 7 | 1 |
Chi et al. [40] | China | Breast cancer | IHC (cyclin D3, NA) | 170/73 | 60 | OS, DFS | High: moderate/strong nucleus staining | NA | 6 | 1 |
Huang et al. [41] | China | Hepatocellular carcinoma | PCR (cyclin D3, NA) | 88/92 | 105.6 | OS | Median | NA | 6 | 2 |
Lopez-Beltran [42] | Spain | Bladder cancer | IHC (cyclin D3, 1000) | 9/150 | 74.7 ± 28.0 | PFS | High: more than 25% cyclin D3-positive cancer cell | 61 | 6 | 2 |
Pruneri et al. [43] | Italy | Laryngeal squamous cell carcinoma | IHC (cyclin D3, 300) | 88/135 | 52 | OS, PFS | High: more than 10% cyclin D3-positive cancer cell | 61.5 | 8 | 1 |
Keyomarsi et al. [44] | USA | Breast cancer | WB (cyclin D3, NA) | 115/272 | 76.8 | OS, DFS | High: higher than the level in normal-cell controls, indicated by a score of more than 2 | 76.8 | 8 | 2 |
Levidou et al. [45] | Greece | Ovarian adenocarcinomas | IHC (cyclin D3, 1000) | 78/14 | 41.5 | OS | Percentage of neoplastic cells with clear nuclear immunoreactivity out of the total number of neoplastic cells counted | 57 | 7 | 2 |
Study | Region | Tumor type | Detection method (number of analyzed cells) | Sample size (high/low) | Follow-up (month) | Endpoints | Cut-off value | Mean age (year) | NOS score | Method |
|---|---|---|---|---|---|---|---|---|---|---|
Moller et al. [46] | USA | Non-Hodgkin lymphoma | IHC (cyclin D3, 1000) | 43/155 | 60 | OS, RFS | High: more than 5% cyclin D3-positive cancer cell | NA | 7 | 2 |
Lopez-Beltran [47] | Spain | Bladder cancer | IHC (cyclin D3, 1000) | 21/138 | 74.8 ± 28.1 | OS | High: more than 13% cyclin D3-positive cancer cell | 61 | 6 | 2 |
Florenes et al. [48] | Norway | Malignant melanoma | IHC (cyclin D3, NA) | 22/85 | 100 | OS, RFS | High: more than 5% cyclin D3-positive cancer cell | NA | 5 | 1 |
Chen et al. [49] | China | Central nervous system lymphoma | IHC (cyclin D3, NA) | 35/31 | 30 | OS | High: more than 20% cyclin D3-positive cancer cell | 52.8 | 7 | 1 |
Sterlacci et al. [50] | Austria | Non-small cell lung cancer | IHC (cyclin D3, NA) | 167/224 | 168 | OS | High: any staining of tumor cell membranes above background level | 62 | 7 | 2 |
Hedberg et al. [51] | Sweden | Renal cell carcinoma | IHC (cyclin D3, 300)/WB | 24/164 | 88.5 | DSS | High: tumors with > 5% positive cells | 65.12 | 6 | 2 |